{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:18:08Z","timestamp":1787008688456,"version":"build-2736575974"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2020,1,4]],"date-time":"2020-01-04T00:00:00Z","timestamp":1578096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005570","name":"Takeda Pharmaceuticals North America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005570","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Nestle Health Science"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K23-CA187185"],"award-info":[{"award-number":["K23-CA187185"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>There are limited data on the most cost-effective sequencing of biologics for ulcerative colitis [UC].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used Markov modelling to identify the most cost-effective position for vedolizumab among biologics for steroid-dependent UC, with a base-case of a 35-year-old male. We assessed three treatment algorithms, with vedolizumab use: prior to an initial anti-tumour necrosis factor alpha [anti-TNF\u03b1] and azathioprine [Algorithm 1]; prior to a second anti-TNF and azathioprine [Algorithm 2]; and prior to colectomy [Algorithm 3]. The initial anti-TNF could be either infliximab or adalimumab. Transition probabilities, costs, and quality-adjusted life-year estimates were derived from published estimates, Medicare, and the Nationwide Inpatient Sample. Primary analyses included 100 trials of 100 000 individuals over 1 year, with a willingness-to-pay threshold of US$100,000. Multiple sensitivity analyses were conducted to assess our findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From a population perspective, when both infliximab and adalimumab are available, vedolizumab was preferred as the first biologic if \u226514% of initial anti-TNF use was adalimumab. If infliximab is the primary biologic, vedolizumab use after infliximab [Algorithm 2] and prior to adalimumab was the most cost-effective strategy. All models were sensitive to biologic pricing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This simulation demonstrated that the most cost-effective strategy in UC depends on the proportion of patients using adalimumab as the initial anti-TNF. If adalimumab was \u226514%, vedolizumab was preferred as the first biologic. When only infliximab was available for first-line therapy, the most cost-effective position of vedolizumab was prior to cycling to adalimumab.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjz212","type":"journal-article","created":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T15:11:13Z","timestamp":1577718673000},"page":"575-587","source":"Crossref","is-referenced-by-count":10,"title":["Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis"],"prefix":"10.1093","volume":"14","author":[{"given":"Frank I","family":"Scott","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of Colorado Anschutz Medical Campus, Aurora, CO,USA"},{"name":"Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Luo","sequence":"first","affiliation":[{"name":"University of Pennsylvania School of Arts and Sciences, Philadelphia PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yash","family":"Shah","sequence":"first","affiliation":[{"name":"Global Evidence & Out, Takeda Pharmaceuticals, Deerfield, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Lasch","sequence":"first","affiliation":[{"name":"US Medical Department, Takeda Pharmaceuticals, Deerfield, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravy K","family":"Vajravelu","sequence":"first","affiliation":[{"name":"Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA"},{"name":"Division of Gastroenterology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronac","family":"Mamtani","sequence":"first","affiliation":[{"name":"Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blair","family":"Fennimore","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of Colorado Anschutz Medical Campus, Aurora, CO,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E","family":"Gerich","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of Colorado Anschutz Medical Campus, Aurora, CO,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D","family":"Lewis","sequence":"first","affiliation":[{"name":"Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA"},{"name":"US Medical Department, Takeda Pharmaceuticals, Deerfield, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,1,4]]},"reference":[{"key":"2020061904033979300_CIT0001","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"2020061904033979300_CIT0002","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"2020061904033979300_CIT0003","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2013.06.010","article-title":"Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"2020061904033979300_CIT0004","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1038\/ctg.2015.63","article-title":"Loss of response to anti-TNFs: definition, epidemiology, and management","volume":"7","author":"Roda","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"key":"2020061904033979300_CIT0005","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1124\/jpet.109.153973","article-title":"The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases","volume":"330","author":"Soler","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"2020061904033979300_CIT0006","doi-asserted-by":"crossref","first-page":"S612","DOI":"10.1093\/ecco-jcc\/jjz046.001","article-title":"OP34 VARSITY: A double-blind, double-dummy, randomised, controlled trial of vedolizumab versus adalimumab in patients with active ulcerative colitis","volume":"13","author":"Schreiber","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2020061904033979300_CIT0007","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"key":"2020061904033979300_CIT0008","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/phar.1561","article-title":"Vedolizumab for the treatment of moderately to severely active ulcerative colitis","volume":"35","author":"Dulai","year":"2015","journal-title":"Pharmacotherapy"},{"key":"2020061904033979300_CIT0009","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"2020061904033979300_CIT0010","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11938-018-0177-z","article-title":"Biosimilars in the treatment of inflammatory bowel disease: supporting evidence in 2017","volume":"16","author":"Scott","year":"2018","journal-title":"Curr Treat Options Gastroenterol"},{"key":"2020061904033979300_CIT0011","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1007\/s10620-019-05594-7","article-title":"Market access analysis of biologics and small-molecule inhibitors for inflammatory bowel disease among US health insurance policies","volume":"64","author":"Dulai","year":"2019","journal-title":"Dig Dis Sci"},{"key":"2020061904033979300_CIT0012","doi-asserted-by":"crossref","first-page":"e000093","DOI":"10.1136\/bmjgast-2016-000093","article-title":"Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis","volume":"3","author":"Yokomizo","year":"2016","journal-title":"BMJ Open Gastroenterol"},{"key":"2020061904033979300_CIT0013","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/ibd\/izx045","article-title":"Assessing the optimal position for vedolizumab in the treatment of ulcerative colitis: a simulation model","volume":"24","author":"Scott","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2020061904033979300_CIT0014","first-page":"1","article-title":"United States life tables, 2007","volume":"59","author":"Arias","year":"2011","journal-title":"Natl Vital Stat Rep"},{"key":"2020061904033979300_CIT0015","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/SLA.0b013e31827d99a2","article-title":"Ileal pouch anal anastomosis: analysis of outcome and quality of life in 3707 patients","volume":"257","author":"Fazio","year":"2013","journal-title":"Ann Surg"},{"key":"2020061904033979300_CIT0016","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1478-7547-7-20","article-title":"Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis","volume":"7","author":"Xie","year":"2009","journal-title":"Cost Eff Resour Alloc"},{"key":"2020061904033979300_CIT0017","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"},{"key":"2020061904033979300_CIT0018","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2036.2009.04027.x","article-title":"Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials","volume":"30","author":"Lichtenstein","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"2020061904033979300_CIT0019","first-page":"CD000478","article-title":"Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis","volume":"9","author":"Timmer","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2020061904033979300_CIT0020","article-title":"SEER Cancer Statistics Review, 1975\u20132010","author":"Howlader","year":"2013"},{"key":"2020061904033979300_CIT0021","volume-title":"IBD Micromedex RED BOOK","year":"2018"},{"key":"2020061904033979300_CIT0022","author":"Centers for Medicare and Medicaid Services"},{"key":"2020061904033979300_CIT0023","author":"HCUP National Inpatient Sample [NIS]"},{"key":"2020061904033979300_CIT0024","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1002\/cncr.20956","article-title":"Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma","volume":"103","author":"Hornberger","year":"2005","journal-title":"Cancer"},{"key":"2020061904033979300_CIT0025","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s10620-015-3886-3","article-title":"Colectomy with permanent end ileostomy is more cost-effective than ileal pouch-anal anastomosis for Crohn\u2019s colitis","volume":"61","author":"Taleban","year":"2016","journal-title":"Dig Dis Sci"},{"key":"2020061904033979300_CIT0026","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.cgh.2006.05.003","article-title":"Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis?","volume":"4","author":"Arseneau","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2020061904033979300_CIT0027","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/ajh.21655","article-title":"Determinants of the optimal first-line therapy for follicular lymphoma: a decision analysis","volume":"85","author":"Olin","year":"2010","journal-title":"Am J Hematol"},{"key":"2020061904033979300_CIT0028","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet"},{"key":"2020061904033979300_CIT0029","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/ajg.2012.89","article-title":"A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"2020061904033979300_CIT0030","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1111\/j.1524-4733.2009.00515.x","article-title":"QALYs: the basics","volume":"12[Suppl 1]","author":"Weinstein","year":"2009","journal-title":"Value Health"},{"key":"2020061904033979300_CIT0031","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0016-5085(00)70353-2","article-title":"Azathioprine for maintenance of remission in Crohn\u2019s disease: benefits outweigh the risk of lymphoma","volume":"118","author":"Lewis","year":"2000","journal-title":"Gastroenterology"},{"key":"2020061904033979300_CIT0032","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/oso\/9780198526629.003.0004","article-title":"Making decision models probabilisitc","volume-title":"Decision Modelling for Health Economic Evaluation","author":"Briggs","year":"2006"},{"key":"2020061904033979300_CIT0033","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/0272989X03255922","article-title":"Probabilistic sensitivity analysis for decision trees with multiple branches: use of the Dirichlet distribution in a Bayesian framework","volume":"23","author":"Briggs","year":"2003","journal-title":"Med Decis Making"},{"key":"2020061904033979300_CIT0034","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.rdc.2019.04.001","article-title":"Are there benefits and risks to biosimilars from a patient perspective?","volume":"45","author":"Kay","year":"2019","journal-title":"Rheum Dis Clin North Am"},{"key":"2020061904033979300_CIT0035","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1136\/gutjnl-2013-305279","article-title":"Individualised therapy is more cost-effective than dose intensification in patients with Crohn\u2019s disease who lose response to anti-TNF treatment: a randomised, controlled trial","volume":"63","author":"Steenholdt","year":"2014","journal-title":"Gut"},{"key":"2020061904033979300_CIT0036","article-title":"Long-term efficacy of vedolizumab for ulcerative colitis","author":"Loftus","year":"2017;11:40011","journal-title":"J Crohns Colitis"},{"key":"2020061904033979300_CIT0037","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1177\/2050640617708952","article-title":"Cost-effectiveness of biological treatment sequences for fistulising Crohn\u2019s disease across Europe","volume":"6","author":"Baji","year":"2018","journal-title":"United European Gastroenterol J"},{"key":"2020061904033979300_CIT0038","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/14737167.2017.1322509","article-title":"Cost-utility of biological treatment sequences for luminal Crohn\u2019s disease in Europe","volume":"17","author":"Rencz","year":"2017","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2020061904033979300_CIT0039","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1093\/ibd\/izy114","article-title":"Cost-effectiveness of different strategies for the treatment of moderate-to-severe ulcerative colitis","volume":"24","author":"Wu","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2020061904033979300_CIT0040","author":"Fein"},{"key":"2020061904033979300_CIT0041","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1053\/j.gastro.2018.06.046","article-title":"Methotrexate is not superior to placebo in maintaining steroid-free response or remission in ulcerative colitis","volume":"155","author":"Herfarth","year":"2018","journal-title":"Gastroenterology"},{"key":"2020061904033979300_CIT0042","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s40264-018-0651-5","article-title":"Thromboembolism with Janus Kinase [JAK] inhibitors for rheumatoid arthritis: how real is the risk?","volume":"41","author":"Scott","year":"2018","journal-title":"Drug Saf"},{"key":"2020061904033979300_CIT0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2019.03.017","article-title":"A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation","author":"Baumrin","year":"2019","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjz212\/32537611\/jjz212.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/14\/5\/575\/33406180\/jjz212.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/14\/5\/575\/33406180\/jjz212.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T06:22:21Z","timestamp":1722234141000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/14\/5\/575\/5696657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,4]]},"references-count":43,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,1,4]]},"published-print":{"date-parts":[[2020,6,19]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz212","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,5]]},"published":{"date-parts":[[2020,1,4]]}}}